MA54960A - Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine - Google Patents
Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amineInfo
- Publication number
- MA54960A MA54960A MA054960A MA54960A MA54960A MA 54960 A MA54960 A MA 54960A MA 054960 A MA054960 A MA 054960A MA 54960 A MA54960 A MA 54960A MA 54960 A MA54960 A MA 54960A
- Authority
- MA
- Morocco
- Prior art keywords
- pyrrolo
- pyrimidine
- amine derivative
- amine
- derivative
- Prior art date
Links
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical class NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019025844 | 2019-02-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54960A true MA54960A (fr) | 2021-12-22 |
Family
ID=72044229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054960A MA54960A (fr) | 2019-02-15 | 2020-02-14 | Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11786534B2 (fr) |
| EP (1) | EP3925669A4 (fr) |
| JP (1) | JP6960064B2 (fr) |
| KR (1) | KR102645237B1 (fr) |
| CN (1) | CN113453764B (fr) |
| AU (1) | AU2020221744B2 (fr) |
| BR (1) | BR112021015813A2 (fr) |
| CA (1) | CA3130049C (fr) |
| MA (1) | MA54960A (fr) |
| MX (1) | MX2021009752A (fr) |
| PH (1) | PH12021551957A1 (fr) |
| SG (1) | SG11202108648TA (fr) |
| TW (1) | TWI828861B (fr) |
| WO (1) | WO2020166680A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2023204304A1 (fr) * | 2022-04-22 | 2023-10-26 | ||
| AU2023256032A1 (en) * | 2022-04-22 | 2024-12-05 | Taiho Pharmaceutical Co., Ltd. | Crystal of 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative |
| TW202529752A (zh) * | 2023-09-29 | 2025-08-01 | 日商大鵬藥品工業股份有限公司 | 7H-吡咯並[2,3-d]嘧啶-4-胺衍生物的結晶 |
| TW202532073A (zh) * | 2023-12-13 | 2025-08-16 | 日商大鵬藥品工業股份有限公司 | 以N-(4-(4-胺基-6-乙炔基-5-(喹啉-3-基)-7H-吡咯并[2, 3-d]嘧啶-7-基)雙環[2. 2. 1]庚烷-1-基)-5-甲基吡-2-甲醯胺或其鹽為有效成分之腦移行性腫瘤治療劑 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080299113A1 (en) | 2005-12-19 | 2008-12-04 | Arnold Lee D | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents |
| US8575164B2 (en) | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
| WO2013118817A1 (fr) | 2012-02-07 | 2013-08-15 | 大鵬薬品工業株式会社 | Composé de quinolyl pyrrolopyrimidine ou son sel |
| SG11201503842PA (en) | 2012-11-15 | 2015-06-29 | Pharmacyclics Inc | Pyrrolopyrimidine compounds as kinase inhibitors |
| WO2015178955A1 (fr) | 2014-05-19 | 2015-11-26 | Eternity Bioscience Inc. | Composés éthynyle hétérobicycliques substitués en tant qu'inhibiteurs de la tyrosine kinase |
| MX390435B (es) | 2016-10-31 | 2025-03-20 | Taiho Pharmaceutical Co Ltd | Inhibidor selectivo de receptor de factor de crecimiento epidermico mutante de insercion de exon 20. |
-
2020
- 2020-02-14 CA CA3130049A patent/CA3130049C/fr active Active
- 2020-02-14 KR KR1020217026415A patent/KR102645237B1/ko active Active
- 2020-02-14 PH PH1/2021/551957A patent/PH12021551957A1/en unknown
- 2020-02-14 EP EP20756674.6A patent/EP3925669A4/fr active Pending
- 2020-02-14 CN CN202080013688.0A patent/CN113453764B/zh active Active
- 2020-02-14 TW TW109104743A patent/TWI828861B/zh active
- 2020-02-14 MX MX2021009752A patent/MX2021009752A/es unknown
- 2020-02-14 SG SG11202108648TA patent/SG11202108648TA/en unknown
- 2020-02-14 WO PCT/JP2020/005684 patent/WO2020166680A1/fr not_active Ceased
- 2020-02-14 MA MA054960A patent/MA54960A/fr unknown
- 2020-02-14 AU AU2020221744A patent/AU2020221744B2/en active Active
- 2020-02-14 US US17/430,208 patent/US11786534B2/en active Active
- 2020-02-14 JP JP2020572322A patent/JP6960064B2/ja active Active
- 2020-02-14 BR BR112021015813-8A patent/BR112021015813A2/pt active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020221744B2 (en) | 2022-06-23 |
| BR112021015813A2 (pt) | 2021-10-13 |
| MX2021009752A (es) | 2021-09-08 |
| TWI828861B (zh) | 2024-01-11 |
| JP6960064B2 (ja) | 2021-11-05 |
| CA3130049C (fr) | 2024-04-16 |
| EP3925669A4 (fr) | 2022-10-26 |
| KR102645237B1 (ko) | 2024-03-07 |
| CN113453764A (zh) | 2021-09-28 |
| AU2020221744A1 (en) | 2021-09-23 |
| CN113453764B (zh) | 2024-04-16 |
| CA3130049A1 (fr) | 2020-08-20 |
| SG11202108648TA (en) | 2021-09-29 |
| WO2020166680A1 (fr) | 2020-08-20 |
| KR20210116598A (ko) | 2021-09-27 |
| PH12021551957A1 (en) | 2022-05-23 |
| JPWO2020166680A1 (ja) | 2021-11-04 |
| EP3925669A1 (fr) | 2021-12-22 |
| US11786534B2 (en) | 2023-10-17 |
| US20220160719A1 (en) | 2022-05-26 |
| TW202045509A (zh) | 2020-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47500A (fr) | Dérivés de pyrrolo [1,2-b]pyridazine | |
| IL276802B1 (en) | Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidine-3-ones | |
| EP3980010A4 (fr) | Composés de pyrazolo[1,5-a]pyrimidine 2,3,5-trisubstitués | |
| IL260923B (en) | History of pyrazolo[5,1-a]pyrazin-4-yl as jak inhibitors | |
| HUE051424T2 (hu) | RET kináz inhibitor szubsztituált pirazolo[1,5-a]piridin vegyületek | |
| DK3523302T3 (da) | Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer | |
| ZA201802842B (en) | [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound | |
| IL289456A (en) | Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds | |
| ZA202105338B (en) | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist | |
| IL290445A (en) | [1,2,4]triazolo[1,5-c]quinazolin-5-amines | |
| EP3744723A4 (fr) | Composé macrocyclique de pyrazolo [1,5-a]pyrimidine substitué | |
| LT3820872T (lt) | Pirolo[1,2-b]piridazino dariniai | |
| IL262673A (en) | A pyrazolo[5,1-a]pyrimidine compound | |
| EP3925669A4 (fr) | Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine | |
| IL269214B (en) | Novel imidazo[5,4-c]quinoline derivatives as lrrk2 inhibitors | |
| DK3679042T3 (da) | Imidazo[1,5-A]pyrazin-derivater som PI3Kdelta-inhibitorer | |
| EP3196199A4 (fr) | N-(pyrrolidin-3-yl)-7h-pyrrolo[2,3-d]pyrimidine-4-amine substituée utilisée en tant qu'inhibiteur de la janus kinase | |
| DK3459953T3 (da) | Hidtil ukendt 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-on-derivat | |
| EP3640253A4 (fr) | Dérivé de 6h-thiéno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazépine | |
| EP3903788A4 (fr) | Composé macrocyclique de pyrazolo[1,5-a] pyrimidine | |
| HUE052997T2 (hu) | JAK kináz inhibitor pirazol[1,5-a]pirimidin származékok |